Rifamail IS Tablet is a fixed-dose combination of Rifampicin and Isoniazid, two essential first-line anti-tuberculosis agents used extensively in standard TB treatment regimens. This combination improves treatment compliance and therapeutic effectiveness.
Rifampicin works by inhibiting bacterial RNA synthesis, while Isoniazid interferes with mycolic acid production in the bacterial cell wall. Together, they provide synergistic action against Mycobacterium tuberculosis.
The tablet formulation ensures accurate dosing, better patient adherence, and reduced pill burden—making it a preferred choice in national TB programs, hospitals, and clinical practice.
For PCD pharma companies, distributors, and exporters, Rifamail IS Tablet is a high-demand, fast-moving product that strengthens the anti-infective and TB therapy portfolio with strong prescriber acceptance and long-term market potential.
Common side effects may include nausea, vomiting, abdominal discomfort, loss of appetite, headache, and orange-red discoloration of body fluids. Serious side effects can include liver toxicity, peripheral neuropathy, allergic reactions, or blood disorders. Immediate medical attention is required if jaundice, severe fatigue, or tingling sensations occur.
Rifamail IS Tablet is indicated for the treatment of tuberculosis as part of combination therapy, in both intensive and continuation phases, as prescribed by a healthcare professional.
Rifamail IS Tablet should be taken exactly as prescribed, preferably on an empty stomach for optimal absorption. Regular monitoring of liver function tests is essential during therapy. Avoid alcohol consumption during treatment. Vitamin B6 (pyridoxine) supplementation may be advised to prevent nerve-related side effects.
Store Rifamail IS Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and do not use beyond the expiry date mentioned on the pack.